Track topics on Twitter Track topics that are important to you
NEW YORK, NY--(Marketwired - March 08, 2017) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview®
(EIO) on Avivagen Inc. (TSX VENTURE: VIV). The full 56-page report is available for download on Crystal Research Associates' website at www.crystalra.com.
Avivagen Inc. (or "the Company") is a life sciences company developing products to replace the use of antibiotics in livestock feed, among other human and animal health products. In the U.S., 80% of all antibiotics sold are not prescribed to patients, but rather are given to poultry and livestock. These drugs are used to ward off disease among animals raised in close quarters and to promote weight gain in animals intended for slaughter. A consequence of such widespread antibiotic use is "superbugs," potentially fatal bacteria that have become resistant to antibiotic treatment.
Rising antibiotic resistance is one of the foremost human health concerns of the century, and Avivagen believes its proprietary, non-antibiotic, hormone-free OxC-beta™ technology holds the key to balancing the food production industry's need for the benefits of antibiotics with society's need to preserve antibiotics for only medically necessary uses. OxC-beta™ is a nature-based ingredient with clinical support for its ability to enhance animal health, immunity, and weight gain. Sales have commenced for its use in livestock feed, with the Company now focused on market access and penetration.
Avivagen is also pursuing important opportunities in human health for OxC-beta™ based on discoveries documenting an extensive safety record in nature for its bioactive component. An OxC-beta™-based product for companion animals has also been developed.
Be the first to hear about Crystal Research Associates' new report releases and upcoming media coverage. Follow us at http://www.crystalra.com/blog for more coverage.
About Crystal Research Associates, LLC
For over a dozen years, Crystal Research Associates, LLC (www.crystalra.com) has successfully articulated the exceptional stories of small- and mid-cap companies to the Wall Street investor community. Our methods are well-established and diverse, from compiling and disseminating objective, factual information for both institutional and retail investor audiences to capitalizing on our expansive line of targeted distribution channels, which include industry-leading financial data and information providers. Our distribution efforts are accompanied by the use of prominent social media channels and by strategic and targeted appearances on national news programs and print media.
Crystal Research Associates is led by Wall Street veterans, Jeffrey Kraws and Karen Goldfarb. Together, Kraws and Goldfarb have built a unique business model, capitalizing on decades of experience as an award-winning sell-side analyst team to produce institutional-quality industry and market research in a manner that is easily understood by investors and consumers. Our firm's approach has been proven successful over the years as our products are published and available on Bloomberg, Thomson Reuters/First Call, Capital IQ, FactSet, and scores of other popular forums.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic news and reports. Crystal Research Associates' compensation was a cash amount of forty thousand U.S. dollars for its services in creating this report and for updates.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.Contact: Jeffrey J. Kraws/Karen B. GoldfarbCrystal Research Associates, LLCP: (212) 851-6685NEXT ARTICLE
MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16 account for 96% of MRSA blood...
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...